NeuroPace (NASDAQ:NPCE) Shares Gap Down – Here’s Why

Posted by George Bondi on May 15th, 2026

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $15.80, but opened at $14.83. NeuroPace shares last traded at $14.8930, with a volume of 69,027 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a report on Friday, March 27th. Wall Street Zen cut shares of NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Wells Fargo & Company raised shares of NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 18th. Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, HC Wainwright lifted their price target on NeuroPace from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.67.

Read Our Latest Research Report on NPCE

NeuroPace Stock Down 0.1%

The stock’s fifty day moving average price is $15.08 and its 200-day moving average price is $15.07. The company has a quick ratio of 4.33, a current ratio of 5.38 and a debt-to-equity ratio of 4.08. The company has a market capitalization of $536.07 million, a price-to-earnings ratio of -24.29 and a beta of 1.92.

NeuroPace (NASDAQ:NPCE – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The business had revenue of $22.00 million during the quarter, compared to the consensus estimate of $21.65 million. On average, sell-side analysts predict that NeuroPace, Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NPCE. Legal & General Group Plc increased its stake in shares of NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares during the last quarter. GSA Capital Partners LLP lifted its stake in NeuroPace by 2.5% in the 3rd quarter. GSA Capital Partners LLP now owns 54,536 shares of the company’s stock valued at $562,000 after purchasing an additional 1,323 shares during the last quarter. Quarry LP grew its holdings in NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after purchasing an additional 1,872 shares during the period. Man Group plc increased its position in NeuroPace by 9.7% during the fourth quarter. Man Group plc now owns 21,626 shares of the company’s stock worth $334,000 after buying an additional 1,920 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in NeuroPace by 23.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company’s stock worth $230,000 after buying an additional 2,778 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

About NeuroPace

(Get Free Report)

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.